Analytical Data
-
基因名
TNFRSF12A
-
简介
TNFRSF12A Protein, the receptor for TNFSF12/TWEAK, acts as a weak apoptosis inducer in specific cell types. It also promotes angiogenesis, endothelial cell proliferation, and may modulate cellular adhesion to matrix proteins. Association with TRAF1, TRAF2, and potentially TRAF3 underscores its involvement in diverse cellular signaling pathways. TNFRSF12A Protein, Human (HEK293, Fc) is the recombinant human-derived TNFRSF12A protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
别名
TNFRSF12A; Fibroblast growth factor-inducible immediate-early response protein 14; FN14; CD266 antigen and tweak-receptor
-
种属
Human
-
表达系统
HEK293
-
标签
C-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NP84-1
-
表达区间
E28-W79
-
蛋白长度
Extracellular Domain
-
分子量
30-40 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF12A, also known as the tumor necrosis factor receptor superfamily member 12A or TRAF receptor-associated factor 2 (TRAF2), has emerged as a significant focus in immunological and cancer research. This receptor is primarily expressed in immune cells and plays a pivotal role in regulating various biological processes, including cell proliferation, survival, and apoptosis. Its involvement in the modulation of inflammatory responses and immune system regulation has placed TNFRSF12A at the center of studies concerning autoimmune diseases and malignancies. Research has shown that the dysregulation of TNFRSF12A signaling pathways can contribute to the progression of several cancers, making it a potential therapeutic target. As a consequence, the development of TNFRSF12A recombinant proteins has gained traction to better understand its functional mechanisms and to explore its potential in therapeutic applications. These recombinant proteins facilitate the elucidation of TNFRSF12A's role in immune modulation and tumorigenesis, thus paving the way for novel treatment strategies that harness the immune system to combat cancer and other related diseases. The ongoing investigations into the biochemical properties and interactions of TNFRSF12A continue to provide insights that are crucial for developing targeted therapies aimed at enhancing immune responses while minimizing side effects associated with conventional treatments.
